Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …

This is the third volume in the new World Health Organization series on histological and
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …

Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …

Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …

Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is
highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine …

Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine
kinase oncogene, the product of the t (9; 22) Philadelphia translocation. Patients with CML in …

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological
and clinical features. The biologic basis of the stereotypical progression from chronic phase …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Although the immune system has long been implicated in the control of cancer, evidence for
specific and efficacious immune responses in human cancer has been lacking. In the case …